Evolving Landscape of ADT in Prostate Cancer

Chair: Fred Saad

Speakers: Andrew Loblaw & Ricardo Rendon

Objectives:

By participating in this learning program, healthcare providers can expect to:

• Describe the role of ADT from a MultiD perspective and apply advanced PCa treatment strategies that take into consideration the risks and benefits of LHRH agonists and antagonists
• Evaluate the benefits and limitations of available ADT options - LHRH agonists, GnRH agonists and antagonists for patients with advanced PCa according to clinical efficacy, CV risk, mechanism of action, route of administration and other practical considerations.
• Design and integrate an individualized treatment plan that includes the most appropriate ADT according to clinical considerations and patient preferences at various stages of the PCa disease continuum, including:
  High risk localized disease
  Biochemical recurrence
  Newly diagnosed metastatic hormone sensitive

ACCREDITATION

This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by CUA. You may claim a maximum of 1 hour of credit.

-------------------------------------

This program has received financial support in the form of an educational grant from Sumitomo Pharma.